Literature DB >> 9200486

Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity.

C Mohan1, L Morel, P Yang, E K Wakeland.   

Abstract

Susceptibility to systemic lupus erythematosus in the NZM2410 murine model maps to Sle1, Sle2, Sle3, and the H2 loci. To unravel how these loci contribute to the pathogenesis of lupus, individual NZM2410-derived genomic intervals bearing these loci have been successfully backcrossed onto the resistant C57BL/6 (B6) background. The focus of this study was to understand how Sle2 on murine chromosome 4 impacts the immune system. Compared with C57BL/6 (B6) mice, B6 mice congenic for Sle2 exhibit a variety of immunophenotypes affecting their B cells. They have an early, but transient, expansion of splenic, CD23(low) B cells. Thereafter, their B cells appear activated by surface phenotype and functional criteria, paralleled by elevated serum levels of polyreactive/polyclonal IgM. Importantly, Sle2 leads to a heightened B cell responsiveness to in vitro stimuli and to in vivo antigenic challenge. Finally, they exhibit increased levels of peritoneal and splenic B1 cells. Thus, Sle2 harbors a gene that leads to B cell hyperactivity and elevated B1 cell formation. However, Sle2 by itself on the normal B6 background is insufficient to generate IgG antinuclear Abs (ANA) or nephritis. By reducing the B cell signaling threshold, Sle2 might serve to amplify an ongoing autoimmune response.

Entities:  

Mesh:

Year:  1997        PMID: 9200486

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset.

Authors:  Uma Sriram; Linda Varghese; Heather L Bennett; Neelakshi R Jog; Debra K Shivers; Yue Ning; Edward M Behrens; Roberto Caricchio; Stefania Gallucci
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  Genetics and systemic lupus erythematosus.

Authors:  B P Tsao; J M Grossman
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

3.  Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.

Authors:  Aleksandar K Stanic; Charles M Stein; Adam C Morgan; Sergio Fazio; MacRae F Linton; Edward K Wakeland; Nancy J Olsen; Amy S Major
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-24       Impact factor: 11.205

4.  Activation of diverse repertoires of autoreactive T cells enhances the loss of anti-dsDNA B cell tolerance.

Authors:  Brian W Busser; Brigette S Adair; Jan Erikson; Terri M Laufer
Journal:  J Clin Invest       Date:  2003-11       Impact factor: 14.808

Review 5.  The non obese diabetic (NOD) mouse: a unique model for understanding the interaction between genetics and T cell responses.

Authors:  William M Ridgway
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 6.  Contribution of B-1a cells to systemic lupus erythematosus in the NZM2410 mouse model.

Authors:  Zhiwei Xu; Laurence Morel
Journal:  Ann N Y Acad Sci       Date:  2015-02-26       Impact factor: 5.691

7.  The NZM2410-derived lupus susceptibility locus Sle2c1 increases Th17 polarization and induces nephritis in fas-deficient mice.

Authors:  Zhiwei Xu; Carla M Cuda; Byron P Croker; Laurence Morel
Journal:  Arthritis Rheum       Date:  2011-03

Review 8.  Genetic dissection of lupus nephritis in murine models of SLE.

Authors:  E K Wakeland; L Morel; C Mohan; M Yui
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 9.  Immune cell signaling aberrations in human lupus.

Authors:  S N Liossis; P P Sfikakis; G C Tsokos
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

10.  PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background.

Authors:  Julie Zikherman; Michelle Hermiston; David Steiner; Kiminori Hasegawa; Andrew Chan; Arthur Weiss
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.